Document is current
Any future updates will be listed below
-
Authors
Penfornis, Alfred https://orcid.org/0000-0002-9635-7674
Down, Su
Seignez, Antoine
Vives, Alizé
Bonnemaire, Mireille
Kulzer, Bernhard
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 16 July 2024
Accepted: 10 December 2024
First Online: 30 January 2025
Declarations
:
: Alfred Penfornis—Advisory panel member for AstraZeneca, MSD, and Novo Nordisk, and speaker for Abbott, Amgen, Bayer MSD, Sanofi, Novo Nordisk, Eli Lilly, and Medtronic; Su Down—Funding from the following companies for providing educational sessions and documents, and advisory boards: Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, MSD, Mylan, Napp, Novo Nordisk, Roche, Sanofi, and Viatris; Antoine Seignez and Alizé Vives—Employees of Carenity, providing consultancy to Sanofi; Mireille Bonnemaire—Employee of Sanofi, holds stocks/shares in Sanofi; Bernhard Kulzer—Speaker’s honoraria and/or advisory boards and/or research grants from Abbott, Ascensia, Bayer, Becton Dickinson, Berlin Chemie, Dexcom, Insulet, Novo Nordisk, Roche, and Sanofi.
: All the participants provided their informed consent. The is not a clinical study or clinical survey and was conducted in accordance with the organization’s intended regulations for qualitative market research studies. This study was exempt from the Institutional Review Board oversight in accordance with exemption guidelines listed in the 2022 EPHMRA (European Pharmaceutical Market Research Association) Code of Conduct for the market research conducted in France, Germany, Italy, Spain, and the UK.
